Sharing the Latest Research Across our Breast Cancer Portfolio

Learn more about our commitment to addressing treatment challenges and improving outcomes for people with breast cancer.

Health Answers by Pfizer

Health Answers by Pfizer is a consumer digital experience powered by generative artificial intelligence that allows you to ask your biggest and smallest health and wellness questions - anytime, anywhere - and receive real-time, relevant responses and next steps.

How Scientists Are Driving the Next Wave of Medical Innovations

For millions of patients around the world, the development of a new treatment or vaccine can be life-changing. But the journey from promising drug candidate to approved product isn't easy.

The Next Era of Decentralized Clinical Trials: The Clinical Trial Anywhere Model

At Pfizer, remote trials and the use of digital tools to conduct clinical trials were implemented long before the pandemic. Increased adoption of modalities like telehealth visits became catalysts for how - and where - clinical research could be done.

Pfizer Buys Into PD-1/VEGF Competition with 3SBio Deal

Pfizer will pay China's 3SBio $1.25 billion up front to access a cancer drug that works similarly to an immunotherapy from Akeso and Summit Therapeutics.

Connected. Active. Involved.

Welcome to the official website for retirees of Pfizer and its legacy organizations.

Pfizer News

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 02, 2025
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
May 31, 2025
Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
May 30, 2025
Astellas and Pfizer's XTANDITM (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
May 22, 2025
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
May 19, 2025
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
April 29, 2025
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
April 26, 2025
Pfizer Announces 2025 Shareholder Meeting Preliminary Results
April 24, 2025
Pfizer Declares Second-Quarter 2025 Dividend
April 23, 2025
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
April 23, 2025
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
April 16, 2025
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
April 14, 2025
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
April 10, 2025
European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
April 01, 2025
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
March 18, 2025
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
March 11, 2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 24, 2025
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
February 13, 2025
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
February 12, 2025
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
February 10, 2025
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
February 04, 2025
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
February 03, 2025

Click here to view all Pfizer News stories.

Join the Pfizer Plus Community Corner

When you join the PfizerPlus.com community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • PfizerPlus.com Community